The Future of Cholesterol Management: Application of PCSK9 Inhibitors in Practice Presurvey

Please take this brief survey to share your experience and knowledge as it relates to the management of cholesterol. Your input will help us to prepare the program and create resources to help in your professional development. The symposium will take place on Sunday, March 18, 2018 at McCormick Place South in Room S100 A.

How many years have you been in clinical practice? *

Approximately how many patients with lipid disorders do you see each week? *

Have you managed patients diagnosed with familial hypercholesterolemia (FH)? *

Yes

No

How familiar are you with the mechanism of action of PCSK9 inhibitors? *

Very Familiar

Familiar

Not Familiar

How familiar are you with the indications for PCSK9 inhibitors? *

Very Familiar

Familiar

Not Familiar

Please rate your level of confidence in the following as it relates to your patients with hyperlipidemia. *

	Confident	Somewhat confident	Not confident	NA
Discussing genetic factors in dyslipidemia	Discussing genetic factors in dyslipidemia - Confident	Discussing genetic factors in dyslipidemia - Somewhat confident	Discussing genetic factors in dyslipidemia - Not confident	Discussing genetic factors in dyslipidemia - NA
Determining 10-year atherosclerotic vascular disease (ASCVD) risk level	Determining 10-year atherosclerotic vascular disease (ASCVD) risk level - Confident	Determining 10-year atherosclerotic vascular disease (ASCVD) risk level - Somewhat confident	Determining 10-year atherosclerotic vascular disease (ASCVD) risk level - Not confident	Determining 10-year atherosclerotic vascular disease (ASCVD) risk level - NA
Selecting lipid-lowering therapy	Selecting lipid-lowering therapy - Confident	Selecting lipid-lowering therapy - Somewhat confident	Selecting lipid-lowering therapy - Not confident	Selecting lipid-lowering therapy - NA
Setting lipid targets and adjusting lipid-lowering therapy dosing accordingly	Setting lipid targets and adjusting lipid-lowering therapy dosing accordingly - Confident	Setting lipid targets and adjusting lipid-lowering therapy dosing accordingly - Somewhat confident	Setting lipid targets and adjusting lipid-lowering therapy dosing accordingly - Not confident	Setting lipid targets and adjusting lipid-lowering therapy dosing accordingly - NA
Optimizing the management of patients with diabetes and dyslipidemia	Optimizing the management of patients with diabetes and dyslipidemia - Confident	Optimizing the management of patients with diabetes and dyslipidemia - Somewhat confident	Optimizing the management of patients with diabetes and dyslipidemia - Not confident	Optimizing the management of patients with diabetes and dyslipidemia - NA

Select how strongly you agree with the following statements *

	Agree	Somewhat agree	Don't agree	NA
Diagnosing FH is a challenge in my practice.	Diagnosing FH is a challenge in my practice. - Agree	Diagnosing FH is a challenge in my practice. - Somewhat agree	Diagnosing FH is a challenge in my practice. - Don't agree	Diagnosing FH is a challenge in my practice. - NA
Long-term management of FH is a challenge in my practice.	Long-term management of FH is a challenge in my practice. - Agree	Long-term management of FH is a challenge in my practice. - Somewhat agree	Long-term management of FH is a challenge in my practice. - Don't agree	Long-term management of FH is a challenge in my practice. - NA
Including PCSK9 inhibitors in the treatment algorithm for patients with dyslipidemia and diabetes is a challenge in my practice	Including PCSK9 inhibitors in the treatment algorithm for patients with dyslipidemia and diabetes is a challenge in my practice - Agree	Including PCSK9 inhibitors in the treatment algorithm for patients with dyslipidemia and diabetes is a challenge in my practice - Somewhat agree	Including PCSK9 inhibitors in the treatment algorithm for patients with dyslipidemia and diabetes is a challenge in my practice - Don't agree	Including PCSK9 inhibitors in the treatment algorithm for patients with dyslipidemia and diabetes is a challenge in my practice - NA

Which of the following barriers do you feel prevent you from optimally diagnosing and treating patients with FH? *

Cost of therapy

Difficulty assessing benefits and risks of therapies

Difficulty setting appropriate lipid targets

Difficulty stratifying ASCVD risk

Adverse events with common therapies

Lack of indicated use for new therapies

Rarity of FH in practice

No barriers

Enter a specific barrier you perceive...

Which of the following barriers do you feel prevent you from optimally diagnosing and treating patients with FH? Enter a specific barrier you perceive...

Please share any additional challenges you encounter in relation to lipid disorders or general feedback

To be entered into the drawing for a $50 gift card, please provide your email. *

You are here